Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024
Paragon 28 (NYSE: FNA), a leading medical device company in the foot and ankle orthopedic market, announced its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024.
For the fourth quarter of 2024, net revenue is expected to range between $71.5 million and $71.8 million, reflecting a growth rate of approximately 18.0% to 18.5% compared to the same period in 2023. For the full year of 2024, net revenue is anticipated to be between $255.9 million and $256.2 million, representing a growth rate of about 18.2% to 18.4% compared to the full year of 2023.
These figures are preliminary and unaudited, subject to adjustments following the completion of quarter-end and year-end closing procedures, and further financial review. Paragon 28's independent registered public accounting firm has not audited, reviewed, or compiled this preliminary financial information.
CEO Albert DaCosta noted that 2024 was a transformative year with significant achievements in growth, innovation, and operational efficiency, positioning the company for sustainable, profitable growth in the future.
Paragon 28 (NYSE: FNA), una delle principali aziende di dispositivi medici nel mercato ortopedico di piedi e caviglie, ha annunciato il suo fatturato netto preliminare non verificato per il quarto trimestre e l'intero anno terminato il 31 dicembre 2024.
Per il quarto trimestre del 2024, si prevede che il fatturato netto si aggiri tra $71,5 milioni e $71,8 milioni, con un tasso di crescita di circa 18,0% a 18,5% rispetto allo stesso periodo del 2023. Per l'intero anno del 2024, il fatturato netto è atteso tra $255,9 milioni e $256,2 milioni, rappresentando un tasso di crescita di circa 18,2% a 18,4% rispetto all'intero anno del 2023.
Queste cifre sono preliminari e non verificate, soggette a modifiche dopo il completamento delle procedure di chiusura di fine trimestre e fine anno, nonché a una revisione finanziaria ulteriore. La società di contabilità pubblica registrata indipendente di Paragon 28 non ha verificato, esaminato o compilato queste informazioni finanziarie preliminari.
Il CEO Albert DaCosta ha sottolineato che il 2024 è stato un anno trasformativo con importanti risultati in termini di crescita, innovazione ed efficienza operativa, posizionando l'azienda per una crescita sostenibile e redditizia in futuro.
Paragon 28 (NYSE: FNA), una empresa líder en dispositivos médicos en el mercado ortopédico del pie y el tobillo, anunció sus ingresos netos preliminares no auditados para el cuarto trimestre y el año completo que terminaron el 31 de diciembre de 2024.
Para el cuarto trimestre de 2024, se espera que los ingresos netos oscilen entre $71.5 millones y $71.8 millones, reflejando una tasa de crecimiento de aproximadamente 18.0% a 18.5% en comparación con el mismo periodo de 2023. Para el año completo de 2024, los ingresos netos se anticipan entre $255.9 millones y $256.2 millones, representando una tasa de crecimiento de alrededor de 18.2% a 18.4% en comparación con el año completo de 2023.
Estas cifras son preliminares y no auditadas, sujetas a ajustes tras la finalización de los procedimientos de cierre de fin de trimestre y fin de año, y a una revisión financiera adicional. La firma de contabilidad pública registrada independiente de Paragon 28 no ha auditado, revisado ni compilado esta información financiera preliminar.
El CEO Albert DaCosta señaló que 2024 fue un año transformador con logros significativos en crecimiento, innovación y eficiencia operativa, posicionando a la empresa para un crecimiento sostenible y rentable en el futuro.
Paragon 28 (NYSE: FNA), 발목 및 발 관절 정형외과 시장의 선도적인 의료기기 회사는 2024년 12월 31일로 종료된 4분기 및 연간 예비 감사 전 순매출을 발표했습니다.
2024년 4분기 순매출은 $71.5백만에서 $71.8백만 사이로 예상되며, 이는 2023년 같은 기간에 비해 약 18.0%에서 18.5%의 성장률을 반영합니다. 2024년 전체 연도에 대한 순매출은 $255.9백만에서 $256.2백만 사이로 예상되며, 이는 2023년 전체 연도에 비해 약 18.2%에서 18.4%의 성장률을 나타냅니다.
이 수치는 참고용이며 감사되지 않았으며, 분기말 및 연말 마감 절차 및 추가 재무 검토 후 조정될 수 있습니다. Paragon 28의 독립 등록 공인 회계 법인은 이 예비 재무 정보를 감사하지 않았으며, 검토하거나 편집하지 않았습니다.
CEO Albert DaCosta는 2024년이 성장, 혁신 및 운영 효율성의 중요한 성과를 거두었던 변혁의 해였다며, 향후 지속 가능하고 수익성 있는 성장을 위한 포지셔닝을 마쳤다고 언급했습니다.
Paragon 28 (NYSE: FNA), une entreprise leader dans le secteur des dispositifs médicaux pour le marché orthopédique du pied et de la cheville, a annoncé ses revenus nets préliminaires non audités pour le quatrième trimestre et l’année complète se terminant le 31 décembre 2024.
Pour le quatrième trimestre de 2024, le revenu net devrait se situer entre 71,5 millions et 71,8 millions de dollars, reflétant un taux de croissance d’environ 18,0 % à 18,5 % par rapport à la même période en 2023. Pour l'année complète de 2024, le revenu net devrait être compris entre 255,9 millions et 256,2 millions de dollars, ce qui représente un taux de croissance d'environ 18,2 % à 18,4 % par rapport à l'année complète de 2023.
Ces chiffres sont préliminaires et non audités, soumis à des ajustements après l'achèvement des procédures de clôture de fin de trimestre et de fin d'année, ainsi qu'à une révision financière ultérieure. La société d’audit public indépendante de Paragon 28 n'a pas audité, examiné ou compilé ces informations financières préliminaires.
Le PDG Albert DaCosta a souligné que 2024 a été une année transformative avec d'importants succès en matière de croissance, d'innovation et d'efficacité opérationnelle, positionnant l'entreprise pour une croissance durable et rentable à l'avenir.
Paragon 28 (NYSE: FNA), ein führendes Unternehmen im Bereich medizinischer Geräte im Bereich Fuß- und Sprunggelenkorthopädie, hat seine vorläufigen, nicht geprüften Nettoumsätze für das vierte Quartal und das Gesamtjahr zum 31. Dezember 2024 bekannt gegeben.
Für das vierte Quartal 2024 wird ein Nettoumsatz zwischen $71,5 Millionen und $71,8 Millionen erwartet, was einer Wachstumsrate von etwa 18,0% bis 18,5% im Vergleich zum gleichen Zeitraum 2023 entspricht. Für das Gesamtjahr 2024 wird ein Nettoumsatz zwischen $255,9 Millionen und $256,2 Millionen antizipiert, was einer Wachstumsrate von etwa 18,2% bis 18,4% im Vergleich zum Gesamtjahr 2023 entspricht.
Diese Zahlen sind vorläufig und nicht geprüft, und sie unterliegen Anpassungen nach Abschluss der Abschlussarbeiten zum Quartalsende und Jahresende sowie einer weiteren finanziellen Überprüfung. Die unabhängige registrierte Wirtschaftsprüfungsgesellschaft von Paragon 28 hat diese vorläufigen Finanzinformationen nicht geprüft, überprüft oder erstellt.
CEO Albert DaCosta bemerkte, dass 2024 ein transformatives Jahr mit bedeutenden Erfolgen in den Bereichen Wachstum, Innovation und betriebliches Management war, wodurch das Unternehmen für ein nachhaltiges und profitables Wachstum in der Zukunft positioniert wurde.
- Preliminary net revenue for Q4 2024 expected between $71.5 million and $71.8 million, reflecting 18.0% to 18.5% growth compared to Q4 2023.
- Full-year 2024 net revenue anticipated between $255.9 million and $256.2 million, showing 18.2% to 18.4% growth compared to 2023.
- Significant achievements in growth, innovation, and operational efficiency in 2024.
- Preliminary financial results are unaudited and subject to adjustments, potentially affecting final numbers.
Insights
The preliminary Q4 2024 revenue range of
For a company with a market cap of
The preliminary nature of these results and pending audit review warrant some caution, but the narrow revenue ranges provided (
The foot and ankle orthopedic market represents one of the fastest-growing segments within orthopedics and Paragon 28's specialized focus is paying dividends. The company's growth trajectory reflects successful market penetration against larger, diversified competitors who treat foot and ankle as just one segment of their portfolio.
The
Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a range of
Preliminary unaudited net revenue for the full year of 2024 is expected to be in a range of
Our estimated unaudited financial results as of and for the fourth quarter and full fiscal year ended December 31, 2024, presented above are preliminary and are subject to the close of the quarter and year, completion of our quarter-end and year-end closing procedures and further financial review. Our independent registered public accounting firm has not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial information. Our actual results may differ from these estimates as a result of the completion of our quarter-end and year-end closing procedures, review adjustments and other developments that may arise between now and the time our financial results for the fourth quarter and full fiscal year are finalized.
“2024 has been a transformative year for Paragon 28, marked by significant achievements in growth, innovation, and operational efficiency. Our efforts across the business have delivered tangible results this year, positioning us for sustainable, profitable growth in the future,” said Albert DaCosta, Chairman and CEO of Paragon 28, “Looking ahead to 2025, we are more excited than ever to build on this momentum and redefine what is possible in the foot and ankle market.”
About Paragon 28, Inc.
Based in
Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foot and ankle patients; that Paragon 28 is positioned for sustainable, profitable growth in the future; and that Paragon 28 is more excited than ever to build on this momentum and redefine what is possible in the foot and ankle market. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results, including the financial results for net revenue for the quarter and full fiscal year ended December 31, 2024, and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Paragon 28’s business in general, see Paragon 28’s current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023 filed with the SEC on August 8, 2024 and its Quarterly Reports on Form 10-Q, as updated periodically with its other lings with the SEC. These forward-looking statements are made as of the date of this press release, January 13, 2025, and Paragon 28 assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113728573/en/
Investor Contact:
Matthew Brinckman
Senior Vice President, Strategy, and Investor Relations
Phone: (741) 336-0435
mbrinckman@paragon28.com
Source: Paragon 28, Inc.
FAQ
What is the preliminary unaudited revenue for Paragon 28 (FNA) in Q4 2024?
How much did Paragon 28's (FNA) revenue grow in Q4 2024 compared to Q4 2023?
What is the expected full-year 2024 revenue for Paragon 28 (FNA)?
How much did Paragon 28's (FNA) revenue grow for the full year of 2024?
Are Paragon 28's (FNA) preliminary financial results for 2024 audited?
What factors contributed to Paragon 28's (FNA) growth in 2024?
What are the potential risks to Paragon 28's (FNA) preliminary financial results for 2024?
